脱敏治疗药物在预致敏肾移植中的应用及进展  

Applications and advances of desensitizing therapeutic agents in pre-sensitized renal transplantation

作　　者：王佳婷 胡雨婷 丁洁 寿张飞[1] Wang Jiating;Hu Yuting;Ding Jie;Shou Zhangfei(Zhejiang University School of Medicine,Hangzhou 310030,China;Zhejiang Chinese Medical University,Zhejiang Shuren University,Hangzhou 310053,China)

机构地区：[1]浙江大学医学院,杭州310030 [2]浙江中医药大学浙江树人学院,杭州310053

出　　处：《中华器官移植杂志》2024年第3期188-193,共6页Chinese Journal of Organ Transplantation

摘　　要：肾移植是治疗终末期肾脏病的主要方式之一,不同中心报道的移植肾10年存活率在75%~80%。研究认为,肾移植是目前降低肾功能衰竭全因死亡率的最佳治疗方式,可明显改善受者生存率与生活质量。预致敏受者由于体内预存有抗人类白细胞抗原抗体,其移植术后发生排斥的风险远高于非致敏受者,但目前随着各类脱敏技术的应用,此类受者的移植率以及术后受者/移植肾存活率已逐渐升高,致敏不再是肾移植的禁忌证。本文主要就预致敏肾移植脱敏治疗药物的进展进行综述和展望。Kidney transplantation(KT)is one primary treatment of end-stage renal disease(ESRD).As reported by different centers,10-year survival rate of transplanted kidneys fluctuates from 75%to 80%.Capable of reducing all-cause mortality in renal failure,KT can significantly improve survival rate and quality-of-life of ESRD patients.The risk of post-transplant rejection is much higher in pre-sensitised recipients than in non-sensitised ones due to the pre-existing anti-human leukocyte antigen antibodies.However,with a rapid development of various desensitisation techniques,transplantation rate and postoperative human/kidney survival rate of recipients have been greatly enhanced.And presensitisation is no longer a contraindication to KT.This review focused upon the latest advances in desensitisation therapeutic agents for pre-sensitised KT.

关 键 词：预致敏 肾移植 脱敏治疗 

分 类 号：R699.2[医药卫生—泌尿科学]